INO

Inovio Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

8.02
-0.30
-3.61%
Pre Market: 8.00 -0.02 -0.25% 08:20 03/31 EDT
OPEN
9.20
PREV CLOSE
8.32
HIGH
9.32
LOW
7.60
VOLUME
31.30M
TURNOVER
--
52 WEEK HIGH
19.36
52 WEEK LOW
1.915
MARKET CAP
1.17B
P/E (TTM)
-6.6380
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of INO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average INO stock price target is 10.43 with a high estimate of 13.00 and a low estimate of 7.00.

EPS

INO News

More
  • SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS AAN, FLR, INO, MGPI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits
  • GlobeNewswire · 8h ago
  • CLASS ACTION UPDATE for SSL, JELD and INO: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
  • ACCESSWIRE · 10h ago
  • INOVIO ALERT: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Securities Fraud Class Action Lawsuit Filed Against INOVIO PHARMACEUTICALS, INC.
  • ACCESSWIRE · 11h ago
  • Cramer's lightning round: 'You do want to buy defense stocks right here'
  • CNBC.com · 12h ago

Industry

Biotechnology & Medical Research
+4.00%
Pharmaceuticals & Medical Research
+4.75%

Hot Stocks

Symbol
Price
%Change

About INO

Inovio Pharmaceuticals, Inc. (Inovio) is a late-stage biotechnology company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
More

Webull offers kinds of Inovio Pharmaceuticals Inc stock information, including NASDAQ:INO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INO stock news, and many more online research tools to help you make informed decisions.